BioCryst Pharmaceuticals is trading at $7.58, down 8.01%, as broad equity and biotech selling weighs on growth stocks.
- During the November 5, 2026 session, the Nasdaq is down 5.10% and XBI is down 5.19%.
- The November 4 earnings report showed revenue above expectations and raised total 2026 revenue guidance; it does not provide a clear company-specific explanation for the decline.